FDA-regulated workflow components enable clinical laboratories to design their own assays for use on the NextSeq 550Dx instrument*.
3 hours hands-on time
A validated, FDA-registered kit enabling the design of diagnostic assays.
5–30 minutes hands-on
Create a sequencing run, monitor run status, analyze sequencing data, and view results with this integrated-on instrument solution.
The TruSight Tumor 170 workflow covers 170 genes associated with common solid tumors. It simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types.
10.5 hours hands-on
A comprehensive assay that targets DNA and RNA variants from the same FFPE tumor sample.
Assay targeting multiple variant types, including tumor mutational burden (TMB) and microsatellite instability (MSI), even from low-quality samples.
Push-button tools
The TruSight Tumor 170 BaseSpace app analyzes reads from DNA and RNA libraries prepared using the TruSight Tumor 170 panel.
Investigate the protein-coding regions of the genome to uncover genetic influences on disease and population health.
6 hours hands-on
This kit provides a low-cost exome sequencing solution that delivers exceptional target coverage over a broad range of read depths.
Comprehensively target disease-associated regions of the exome with high analytical sensitivity and specificity.
~5.5 hours hands-on
Two panels offer options to target up to 6700 genes associated with human disease, with high coverage
Advancements in our understanding of genetics is changing the practice of medicine and enabling genomics-based healthcare.
Illumina offers molecular diagnostic options for cystic fibrosis and next-generation sequencing-based assay development.
To simplify analysis and help you easily obtain information relevant to your specific questions, Illumina offers a number of tools for data management.
* Contact your Illumina representative for more information about IVD development partnerships
United States:
The NextSeq 550Dx instrument is intended for targeted sequencing of DNA libraries from human genomic DNA extracted from peripheral whole blood or formalin-fixed, paraffin-embedded (FFPE) tissue, when used for in vitro diagnostic (IVD) assays performed on the instrument. The NextSeq 550Dx instrument is not intended for whole genome or de novo sequencing. The NextSeq 550Dx instrument is to be used with registered and listed, cleared or approved, IVD reagents and analytical software.
European Union:
The NextSeq 550Dx instrument is intended for sequencing of DNA libraries when used with in vitro diagnostic (IVD) assays performed on the instrument. The NextSeq 550Dx instrument is to be used with specific registered, certified or approved IVD reagents and analytical software.